Candida krusei: 100% Resistant to Standard Treatment
Have you finished treatment, but your UTI is still there? If your symptoms persist or return within days of completing a course of antifungal treatment, the treatment may have targeted the wrong species. C. krusei is 100% resistant to the most commonly prescribed antifungal – no strain has ever responded. You are not doing anything wrong. The treatment is simply the wrong one for this organism. PCR testing confirms whether C. krusei is the cause.
Candida krusei (recently reclassified as Pichia kudriavzevii) is a yeast species best known for its complete, intrinsic resistance to the most commonly prescribed antifungal. Unlike C. albicans or C. glabrata, where resistance may develop over time, C. krusei is born resistant – every single isolate (Pappas et al., 2016).
This makes identification before treatment absolutely critical. If standard first-line antifungal therapy is prescribed for a UTI caused by C. krusei, the treatment will fail every time. Alternative approaches are required, and these can only be chosen with confidence once the organism has been identified by PCR.
Why C. krusei Matters
Standard treatment will never work. This is not acquired resistance – it is intrinsic. If you have been treated multiple times and your symptoms keep returning, C. krusei should be considered.
The Prophylaxis Paradox: How Prevention Creates C. krusei
This is the central irony of C. krusei. When cancer patients begin chemotherapy, their immune systems become severely weakened. To protect them from fungal infections, clinicians prescribe prophylactic antifungal treatment – a standard, evidence-based practice that saves lives.
But here is the problem: that prophylactic antifungal kills every susceptible Candida species in the body – C. albicans, C. tropicalis, C. parapsilosis. With the competition eliminated, the one species that is 100% resistant to that treatment – C. krusei – now has the entire territory to itself. It overgrows unopposed.
This is called selection pressure, and it is why C. krusei is almost exclusively found in patients who have received antifungal prophylaxis. The very treatment designed to prevent fungal infection is what creates the conditions for this particular species to thrive. It is not a failure of care – it is a predictable biological consequence that clinicians should anticipate and test for.
This is why PCR matters in oncology. If a cancer patient on antifungal prophylaxis develops a breakthrough UTI or fungal infection, C. krusei should be the first species considered. PCR testing confirms it in a single test, preventing wasted courses of the very treatment that cannot work.
Cancer, Chemotherapy, and C. krusei
C. krusei is fundamentally a cancer-associated pathogen. Unlike other Candida species that affect the general population, C. krusei is concentrated in specific clinical populations:
- Patients with haematological malignancies – leukaemia and lymphoma patients undergoing chemotherapy are the single largest risk group. Their immune systems are profoundly suppressed, and antifungal prophylaxis is standard practice
- Bone marrow and stem cell transplant recipients – prolonged immunosuppression lasting months, combined with mandatory antifungal prophylaxis, creates ideal selection pressure for C. krusei
- Solid tumour patients on intensive chemotherapy – particularly when chemotherapy causes neutropaenia (dangerously low white blood cell counts)
- ICU patients on broad-spectrum antimicrobials – extended hospital stays with multiple antimicrobial agents eliminate competing organisms
In South Africa, private oncology centres in Johannesburg (Sandton Oncology, Wits Donald Gordon), Cape Town (GVI Oncology, Groote Schuur), and Durban (Umhlanga Oncology) routinely prescribe antifungal prophylaxis. If you are being treated at any of these centres and develop a breakthrough infection, PCR testing for C. krusei should be discussed with your oncologist.
How C. krusei Resistance Differs from C. glabrata
Both C. krusei and C. glabrata are described as "resistant" – but the resistance is fundamentally different, and the distinction matters for your treatment:
- C. glabrata develops resistance over time – it may initially respond to standard antifungal treatment, but resistance builds with repeated exposure. This is acquired resistance. Some C. glabrata strains are still susceptible
- C. krusei is resistant from birth – every single isolate, everywhere in the world, is resistant to standard first-line therapy. This is intrinsic resistance. No strain has ever responded. No strain ever will
What this means for you: if your clinician suspects a resistant Candida species, the treatment approach differs depending on which one. PCR testing distinguishes between them definitively, ensuring the correct alternative therapy is chosen from the start.
Could C. krusei Be Behind Your UTI?
Symptoms
The symptoms of a C. krusei UTI are identical to any other fungal UTI – and that is precisely the problem. There is no symptom that says "this is C. krusei." The organism reveals itself not through what you feel, but through what happens when treatment fails. If you have completed standard antifungal treatment and your UTI persists unchanged, C. krusei should be at the top of the list.
Burning urination – identical to bacterial or other fungal UTIs. Standard dipsticks will not detect yeast.
Urgency and frequency – constant need to urinate even when the bladder is empty.
Pelvic pain or pressure – dull ache in the lower abdomen.
Treatment failure – the key indicator. If standard antifungal therapy does not resolve your UTI, C. krusei may be the cause.
Recurrent episodes – UTI returns within days or weeks of completing treatment.
Who Is Most at Risk?
- Patients with previous antifungal exposure – prophylactic antifungal treatment selects for C. krusei by eliminating susceptible species
- Cancer patients on chemotherapy – leukaemia, lymphoma, and solid tumours requiring antifungal prophylaxis
- Bone marrow transplant recipients – prolonged immunosuppression and antifungal prophylaxis
- Hospitalised and ICU patients – most C. krusei infections are healthcare-associated
- People with diabetes – repeated antifungal courses for recurrent yeast infections can select for resistant species like C. krusei; elevated glucose supports yeast overgrowth
- Anyone with a persistent fungal UTI – if symptoms do not resolve after treatment, the wrong species may have been assumed
The Diabetes Connection
Diabetes creates a dual risk for C. krusei. First, elevated blood glucose supports yeast overgrowth generally. Second – and more importantly – diabetic patients who experience recurrent yeast infections (vaginal thrush, oral thrush, or UTIs) often receive repeated courses of standard antifungal treatment. Each course eliminates susceptible Candida species while leaving resistant species untouched. Over time, this repeated selection pressure can shift the patient's Candida population towards resistant species like C. krusei and C. glabrata. If you have diabetes and your yeast infections keep returning despite treatment, PCR testing can identify whether a resistant species has taken hold.
Test before you treat. PCR testing identifies C. krusei in a single test, preventing wasted courses of ineffective treatment and guiding clinicians to the correct alternative therapy from the start.
Yeast UTI vs Bacterial UTI: Why Standard Tests Miss C. krusei
A standard urine dipstick detects bacteria – it looks for nitrites and leukocyte esterase produced by bacterial infection. Yeast species like C. krusei do not produce these markers, which means a standard dipstick will come back negative even when a yeast UTI is present.
This is one of the most common reasons fungal UTIs go undiagnosed. You have real symptoms – burning, urgency, frequency – but the dipstick says "no infection." You may be told your symptoms are non-specific, psychosomatic, or that you should drink more water. In reality, your UTI is caused by a yeast species that the test simply cannot detect.
PCR testing solves this by identifying the DNA of the organism directly – bacteria AND yeast, in a single test, with species-level accuracy.
C. krusei in South Africa
C. krusei is primarily hospital-associated, but the risk factors that drive it are present across South Africa's healthcare spectrum.
In Private Healthcare
Cancer patients at private oncology centres in Johannesburg, Cape Town, or Durban are the group most likely to encounter C. krusei. Prophylactic antifungal treatment during chemotherapy selects for C. krusei by eliminating susceptible species. If a patient on prophylaxis develops a breakthrough infection, C. krusei should be the first species considered.
In Public Healthcare
In public hospitals, where standard antifungal therapy is widely used because it is affordable and on the Essential Medicines List, C. krusei breakthrough infections can be harder to manage. Access to alternative antifungal treatments is limited in many public facilities.
For Travellers
If you are receiving medical care in South Africa and develop a UTI during or after hospitalisation, healthcare-associated Candida species like C. krusei are a possibility. PCR testing ensures accurate information for your healthcare provider at home.
Epicentre's UTI PCR Panel
UTI Package – 11-Target PCR Screen
How the Home Test Kit Works
If you cannot visit an Epicentre branch, order the UTI home collection kit and test from anywhere in South Africa.
Order
Order from the Epicentre shop. Discreet, unmarked packaging.
Collect
Follow clear instructions to collect your urine sample at home.
Return
Post it back using the prepaid return label included in the kit.
Results
Colour-coded results digitally within 5 – 7 working days.
Frequently Asked Questions
Why Will My UTI Not Clear?
What Is the Difference Between a Yeast UTI and a Bacterial UTI?
Have You Finished Treatment but Your UTI Is Still There?
Can Diabetes Increase C. krusei Risk?
How Does the Home Test Kit Work?
Do I Need a Doctor's Referral?
References
- Pappas, P.G. et al. (2016). Clinical practice guideline for the management of candidiasis. Clinical Infectious Diseases, 62(4), e1 – e50.
